MELLARIL-S
LOE ApproachingNDAORALSUSPENSION
Approved
Oct 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 13h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MELLARIL-S is an oral suspension small-molecule antipsychotic approved in 1978 by Novartis. The mechanism of action and specific indications are not documented in available data, though the product class suggests treatment of psychiatric conditions. This legacy product represents a mature therapeutic option in the antipsychotic space.
LOE Approaching
As a legacy product approaching loss of exclusivity, the brand team is likely small and focused on maintenance rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MELLARIL-S currently has zero linked job openings, reflecting its LOE-approaching status and mature market position. Career opportunities are limited to maintenance-focused roles with minimal growth trajectory or strategic importance within Novartis' portfolio.
Brand ManagerField Sales Representative
Worked on MELLARIL-S at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.